

Applicants: Eric Rose et al.
U.S. Serial No.: 09/053,872
Filed: April 1, 1998
Page 2

Please amend the subject application as follows:

In the specification:

Please amend the Specification under the provisions of 37 C.F.R. §1.21(b) as follows. A marked up version of the amended specification wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit A.

- JK
7/15/02
- (a) Please replace the paragraph at page 13, lines ¹⁶~~17~~-35 and page 14, lines ⁴~~1-12~~, with the following paragraph:

-
- BL
- 1) Oligonucleotides for producing Factor IXmi (Ser365-Nnn)
3'-W ACA GTT CCT CTA NNN CCC CCT GGG GTA V-5' (SEQ ID No.:1)
where
W is T, 3'-GT or 3'-AGT
V is C, 3'-CA or 3'-CAA
NNN is the complement to a DNA codon for any one of the
standard amino acids other than serine.
- 2) Oligonucleotides for prodicing FACTOR IXmi (Asp269-Nnn)
3'-W TTC ATG TTA GTA NNN TAA CGC GAA GAC V-5' (SEQ ID No.:2)
where
W is A, 3'-TA, or 3'-TTA
V is C, 3'-CT, or 3'-CTT
NNN is the complement to a DNA codon for any one of the
standard amino acids other than aspartic acid and cysteine.
- 3) Oligonucleotides for producing Factor IXmi (His221-Nnn)
3'-TTA CAT TGA CGA CGG NNN ACA CAA CTT TGA CCA-5' (SEQ ID

Applicants: Eric Rose et al.
U.S. Serial No.: 09/053,872
Filed: April 1, 1998
Page 3

B1
No.:3)

where

W is A, 3'-AA, or 3'-TAA

V is C, 3'-CC, or 3'-CCA

NNN is the complement to a DNA codon for any one of the standard amino acids other than histidine and cysteine.--

-
- (b) Please replace the paragraph at page 1, lines 5-10, with the following paragraph:

B2
-- This application is a continuation-in-part of PCT International Application No. PCT/US97/08282, filed May 15, 1997 which is a continuation-in-part of United States Application Serial No. 08/648,561, filed May 16, 1996, now U.S. Patent No. 5,839,443, issued November 24, 1998, the contents of each of which are incorporated by reference in their entireties into the present application.--

-
- (c) Please replace the paragraph at page 6, lines 15-35 and page 7, line 1, with the following paragraph:

B3
-- This invention further provides that the patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery or any surgery in which obligate clamping of a blood vessel is required. The patient may be subjected to extracorporeal blood circulation during any kind of cardiac surgery, including bypass grafting, valve replacement, congenital repair heart surgery and heart transplantation. The